Stockreport

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

SAB Biotherapeutics, Inc.  (SABS) 
PDF In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection, which causes p [Read more]